Opthea Limited
Overview
Opthea Limited is a biopharmaceutical company focused on developing and commercializing therapies to treat highly prevalent and progressive retinal diseases. The company's lead product candidate, OPT-302, targets VEGF-C/D to improve outcomes in patients with wet age-related macular degeneration (wet AMD).
Therapeutic areas
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to Opthea Limited in our records. Events are linked by company name and identifier, so this is not proof that none exist; check the FDA's own databases before relying on it.
Is this Opthea Limited?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.